Bioventix Valuation
Is 51B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 51B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 51B (€46.4) is trading above our estimate of fair value (€43.08)
Significantly Below Fair Value: 51B is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 51B?
Key metric: As 51B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 51B's PE Ratio? | |
|---|---|
| PE Ratio | 25.3x |
| Earnings | UK£8.10m |
| Market Cap | UK£204.87m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.6x |
| Enterprise Value/EBITDA | 18.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 51B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12x | ||
FYB Formycon | 12.9x | 30.8% | €826.3m |
BIO3 Biotest | 6.4x | -67.2% | €1.3b |
2INV 2invest | 12.1x | n/a | €60.9m |
PSG PharmaSGP Holding | 16.6x | 14.6% | €302.2m |
51B Bioventix | 25.3x | n/a | €204.9m |
Price-To-Earnings vs Peers: 51B is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (12x).
Price to Earnings Ratio vs Industry
How does 51B's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 51B is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the European Biotechs industry average (25.3x).
Price to Earnings Ratio vs Fair Ratio
What is 51B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 51B's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.46
7D
-3.4%
1Y
2.1%
Pharming Group
€498.9m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
-1.0%
1Y
-32.7%
Merck
US$249.2b
Operates as a healthcare company worldwide.
6MK
US$93.10
7D
-1.0%
1Y
-0.1%